ICU

SeaStar Medical Holding Corporation is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation in acute and chronic conditions. The company's lead product, the Selective Cytopheretic Device (SCD), is designed to remove activated neutrophils from blood during extracorporeal therapy to modulate inflammation. SeaStar Medical is initially targeting applications in acute kidney injury requiring dialysis and other critical care conditions characterized by excessive inflammation. The company's technology platform aims to address unmet medical needs in life-threatening conditions driven by dysregulated immune responses.